Aurora Cannabis Inc. filings document its U.S. reporting as a Canadian foreign private issuer and the formal disclosure record for its medical cannabis operations. Recent Form 6-K reports furnish news releases, material change reports, sales agreements and offering documents tied to product launches, financial results, acquisitions, governance matters and capital-structure activity.
The filings include disclosure for an at-the-market common-share program under shelf registration documents, material change reports on corporate transactions, and exhibits incorporated by reference into Form F-10 and Form S-8 registration statements. They also record Aurora's operating updates across regulated cannabis markets, GMP-certified manufacturing network, shareholder voting matters and executive-level governance disclosures.
Aurora Cannabis Inc. reported that it has been granted Plant Breeders' Rights in Canada for two proprietary cannabis cultivars developed through its internal breeding program. These rights give Aurora exclusive authority to grow, propagate, and sell finished products from these specific varieties in Canada.
The protected cultivars are SOT20R07-007, marketed as Farm Gas™, and SOT20R07-005, marketed as Driftwood Diesel™, developed at the Aurora Coast research facility in British Columbia. These strains are core medical cannabis products available to patients in Germany, Poland, the UK, Canada, and Australia, and Aurora states that this protection, alongside recent European variety protection, enhances its global competitive position in medical cannabis.
Aurora Cannabis Inc. is expanding its global medical cannabis portfolio with new product launches across Canada, Europe and Australia. The rollout, occurring between now and June, adds dried flower, pre-rolls and precisely dosed pastilles that align with the company’s medical-first strategy and GMP-certified production network.
New offerings in Germany and Poland broaden high-THC dried flower choices, while Australian launches introduce discreet, long-lasting pastilles featuring multiple cannabinoids. In Canada, Aurora is adding new dried flower and pre-roll products under its WMMC and San Raf brands, aiming to meet patient and prescriber demand in regulated medical markets.
Aurora Cannabis Inc. reported that a wholly owned subsidiary, Aurora Sub, has indirectly purchased 100% of the shares of 9869247 Canada Limited (Safari Flower Company), an established EU GMP certified cannabis cultivator and manufacturer.
The aggregate consideration for the Safari Flower Company transaction is valued at $26.5 million, which includes a $2 million cash payment that is contingent on certain conditions. At closing, Aurora issued the selling shareholder 2,417,180 common shares and paid $15 million in cash, with amounts subject to customary post-closing adjustments.
Aurora Cannabis Inc. has acquired Safari Flower Company for aggregate consideration valued at $26.5 million. The deal includes 2,417,180 common shares, $15 million in cash at closing, and an additional $2 million cash payment contingent on certain conditions.
Safari Flower operates a 59,000 square foot EU GMP certified indoor cultivation and manufacturing facility in Ontario, which will add tightly aligned capacity to Aurora’s existing network. Aurora plans to use this expanded EU GMP capacity to supply high-margin international medical cannabis markets such as Germany, Australia, Poland, and the UK.
The company expects the acquisition to contribute positively to Adjusted EBITDA in fiscal year 2027, with incremental benefits in fiscal 2028 and beyond as operations are optimized, leveraging Aurora’s plant science and operational expertise.
Aurora Cannabis Inc. filed a Form 6-K highlighting that it has been named to The Globe and Mail’s 2026 Women Lead Here list for the second consecutive year. This editorial benchmark recognizes publicly traded Canadian companies with strong executive-level gender diversity.
Aurora is one of 85 companies on the list with 50% female representation on its executive leadership team, underscoring its stated focus on developing a diverse pipeline of female talent and fostering an inclusive leadership culture. The company positions this recognition as aligned with its broader commitment to people, patients, and communities it serves across global medical cannabis markets.
Aurora Cannabis Inc. filed a report highlighting two main updates. The company will participate in TD Cowen's 46th Annual Health Care Conference in Boston, where CFO Simona King will join a fireside chat and investor meetings on March 2, 2026.
Aurora also announced it has completed its previously announced transaction with Bevo Agtech Inc., referred to as the Bevo Transaction. Further details of this transaction are available in the company’s February 4, 2026 press release on SEDAR+.
Aurora Cannabis Inc. outlines two major steps: restructuring its investment in Bevo Agtech and launching a new at-the-market equity program of up to US$100,000,000 in common shares.
Under a definitive Bevo Agreement, Aurora will exchange its Bevo Agtech common shares for preferred shares that pay a 5% annual dividend, plus 30% of eligible Bevo cash flow, rising to 40% after 15 years, and 30% of proceeds on a Bevo liquidation event. Bevo’s results will be treated as discontinued operations and deconsolidated from Aurora’s financial statements after closing, and Aurora will receive $5.5 million in cash for shareholder loans and retain earnout rights of up to $25 million and $15 million tied to two facilities. Separately, Aurora signed a Sales Agreement with TD Securities (USA) LLC to sell shares from time to time on the Nasdaq Capital Market as an at-the-market distribution, with proceeds earmarked for strategic and accretive uses, including cultivation expansion and M&A.
Aurora Cannabis Inc. has entered into a common share sales agreement with TD Securities (USA) LLC that allows the company, from time to time, to sell common shares into the U.S. market. The agreement covers up to US$100,000,000 of common shares, referred to as Placement Shares.
Sales will be made through TD Securities acting as agent and/or principal under Aurora’s existing Form F-10 shelf registration and corresponding Canadian base shelf prospectus, which register up to US$250,000,000 of various securities. Shares may be sold on Nasdaq or other permitted U.S. trading markets, with trades settled in the ordinary course and Aurora receiving net proceeds after commissions and fees.
Aurora Cannabis Inc. has entered into a common share sales agreement with TD Securities (USA) LLC that allows the company, from time to time, to sell common shares into the U.S. market. The agreement covers up to US$100,000,000 of common shares, referred to as Placement Shares.
Sales will be made through TD Securities acting as agent and/or principal under Aurora’s existing Form F-10 shelf registration and corresponding Canadian base shelf prospectus, which register up to US$250,000,000 of various securities. Shares may be sold on Nasdaq or other permitted U.S. trading markets, with trades settled in the ordinary course and Aurora receiving net proceeds after commissions and fees.
Aurora Cannabis Inc. established an at-the-market share offering program that permits it to issue and sell up to U.S.$100 million of common shares from treasury through U.S. markets over time at prevailing prices.
The company plans to use any net proceeds only for strategic and accretive purposes, including increasing cultivation capacity and pursuing mergers and acquisitions. Sales will occur on the NASDAQ or other U.S. marketplaces, or via privately negotiated transactions, under a sales agreement with TD Securities (USA) LLC and a filed prospectus supplement to its existing base shelf prospectus and Form F-10 registration statement.
Aurora Cannabis Inc. established an at-the-market share offering program that permits it to issue and sell up to U.S.$100 million of common shares from treasury through U.S. markets over time at prevailing prices.
The company plans to use any net proceeds only for strategic and accretive purposes, including increasing cultivation capacity and pursuing mergers and acquisitions. Sales will occur on the NASDAQ or other U.S. marketplaces, or via privately negotiated transactions, under a sales agreement with TD Securities (USA) LLC and a filed prospectus supplement to its existing base shelf prospectus and Form F-10 registration statement.
Aurora Cannabis Inc. reported fiscal Q3 2026 results showing continued strength in its global medical cannabis franchise and solid cash generation. Total net revenue was $94.2 million, up 7% year over year, driven by a record $76.2 million in medical cannabis net revenue, which supplied most of the company’s sales and adjusted gross profit.
Consolidated adjusted gross margin before fair value adjustments was 62%, while adjusted EBITDA was $18.5 million, slightly below the prior year but up sequentially. Free cash flow reached $15.5 million, reflecting better operating cash and modest maintenance capex. Adjusted net income was steady at $7.2 million.
The company plans to exit selected lower-margin Canadian consumer markets starting Q4 FY26 to focus further on higher-margin medical cannabis, expecting lower adjusted SG&A and better margins after some one-time Q4 costs. Aurora also agreed to restructure its Bevo Agtech investment into preferred shares with a 5% dividend and a share of Bevo cash flows, after which Bevo will be deconsolidated and treated as a discontinued operation. In parallel, Aurora established a new at-the-market equity program allowing issuance of up to US$100 million of common shares from treasury for strategic and accretive uses such as added cultivation capacity and potential M&A.
Aurora Cannabis Inc. reported fiscal Q3 2026 results showing continued strength in its global medical cannabis franchise and solid cash generation. Total net revenue was $94.2 million, up 7% year over year, driven by a record $76.2 million in medical cannabis net revenue, which supplied most of the company’s sales and adjusted gross profit.
Consolidated adjusted gross margin before fair value adjustments was 62%, while adjusted EBITDA was $18.5 million, slightly below the prior year but up sequentially. Free cash flow reached $15.5 million, reflecting better operating cash and modest maintenance capex. Adjusted net income was steady at $7.2 million.
The company plans to exit selected lower-margin Canadian consumer markets starting Q4 FY26 to focus further on higher-margin medical cannabis, expecting lower adjusted SG&A and better margins after some one-time Q4 costs. Aurora also agreed to restructure its Bevo Agtech investment into preferred shares with a 5% dividend and a share of Bevo cash flows, after which Bevo will be deconsolidated and treated as a discontinued operation. In parallel, Aurora established a new at-the-market equity program allowing issuance of up to US$100 million of common shares from treasury for strategic and accretive uses such as added cultivation capacity and potential M&A.